The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 533 KB) and Technical Notes (PDF, 752 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 19.29

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Both Sexes, 2004-2010
Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 169,687 68.1 67.8 68.4 89.0 88.3 89.7 75.8 75.4 76.1 57.4 56.9 57.9
1 Hodgkin Lymphoma 14,949 85.3 84.6 86.0 96.4 95.3 97.3 89.4 88.7 90.1 52.8 49.9 55.6
2 Non-Hodgkin lymphoma 150,164 66.9 66.6 67.3 87.0 86.1 87.8 74.0 73.5 74.4 58.1 57.6 58.7
2(a) Non-Hodgkin lymphoma, B-cell 137,405 67.4 67.0 67.7 88.0 87.0 88.9 74.9 74.5 75.3 58.8 58.2 59.3
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 7,176 67.6 66.3 68.8 88.0 86.8 89.0 35.4 33.0 37.8 14.0 10.5 17.9
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 124,162 67.3 67.0 67.7 88.2 86.0 90.1 76.3 75.9 76.7 59.0 58.4 59.5
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 29,600 76.4 75.6 77.1 - - - 85.3 84.4 86.2 70.4 69.2 71.5
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 26,077 79.2 78.4 80.0 - - - 88.1 87.2 89.0 73.4 72.2 74.6
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 114 41.6 29.9 52.9 - - - 51.2 30.8 68.3 36.1 21.9 50.5
2(a) 2.1.3. Mantle-cell lymphoma 3,409 55.6 53.2 57.8 - - - 67.5 64.4 70.5 46.0 42.6 49.2
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 2,699 78.2 75.5 80.7 - - - 85.1 81.7 87.8 74.1 70.2 77.6
2(a) 2.2.1. Lymphoplasmacytic lymphoma 1,207 74.0 69.7 77.8 - - - 80.7 75.0 85.3 70.1 64.0 75.3
2(a) 2.2.2. Waldenstrom macroglubulinemia 1,492 81.5 77.9 84.6 - - - 88.3 84.0 91.5 77.3 71.9 81.7
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 32,750 60.5 59.8 61.1 86.4 82.6 89.4 69.9 69.0 70.7 50.7 49.6 51.8
2(a) 2.3.1. DLBCL, NOSc 32,385 60.3 59.6 61.0 87.3 83.5 90.2 69.8 68.9 70.6 50.7 49.6 51.8
2(a) 2.3.2. Intravascular large B-cell lymphoma 36 54.8 34.6 71.2 - - - - - - - - -
2(a) 2.3.3. Primary effusion lymphoma 54 22.5 10.8 36.8 - - - 24.8 11.6 40.5 - - -
2(a) 2.3.4. Mediastinal large B-cell lymphoma 275 81.8 75.3 86.8 - - - 86.4 80.2 90.7 - - -
2(a) 2.4. Burkitt lymphoma/leukemia 2,200 58.3 56.0 60.6 88.6 85.2 91.3 55.8 52.8 58.6 31.0 25.1 37.1
2(a) 2.5. Marginal-zone lymphoma (MZL) 8,856 90.0 88.8 91.2 98.2 87.7 99.7 92.9 91.6 93.9 87.4 85.1 89.3
2(a) 2.5.1. Splenic MZL 756 84.8 80.1 88.4 - - - 87.7 82.3 91.5 81.8 74.3 87.3
2(a) 2.5.2. Extranodal MZL, MALTc type 5,326 94.0 92.4 95.3 97.4 82.7 99.6 95.7 94.2 96.8 92.2 89.0 94.5
2(a) 2.5.3. Nodal MZL 2,774 83.5 81.1 85.6 - - - 87.8 84.9 90.1 79.9 76.1 83.1
2(a) 2.6. Follicular lymphoma 18,039 86.1 85.3 86.9 91.8 75.9 97.4 90.6 89.8 91.4 79.9 78.3 81.5
2(a) 2.7. Hairy-cell leukemia 1,470 93.6 90.8 95.5 - - - 97.6 95.8 98.7 82.5 74.7 88.1
2(a) 2.8. Plasma cell neoplasms 28,523 44.6 43.8 45.4 - - - 57.4 56.3 58.6 34.8 33.7 35.8
2(a) 2.8.1. Plasmacytoma 1,778 65.0 61.8 67.9 - - - 77.4 73.8 80.5 48.7 43.5 53.7
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 26,745 43.3 42.4 44.1 - - - 55.7 54.5 56.9 34.0 32.9 35.1
2(a) 2.9. Heavy chain disease 25 66.6 34.1 85.7 - - - - - - - - -
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 6,067 67.5 65.7 69.2 83.3 65.2 92.5 75.4 73.2 77.5 62.1 59.4 64.6
2(b) Non-Hodgkin lymphoma, T-cell 10,320 63.1 61.9 64.2 83.3 81.0 85.5 66.3 64.9 67.7 49.6 47.1 52.0
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 884 62.4 58.7 65.8 84.5 80.5 87.8 44.8 39.3 50.2 8.0 2.1 19.0
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 9,351 63.4 62.2 64.6 82.7 79.6 85.4 68.1 66.6 69.5 50.7 48.2 53.2
2(b) 2.1. Mycosis fungoides/Sezary syndrome 2,319 89.4 87.1 91.4 94.9 77.3 98.9 93.0 90.9 94.7 80.7 74.3 85.6
2(b) 2.1.1. Mycosis fungoides 2,254 90.6 88.3 92.5 94.9 77.3 98.9 93.6 91.5 95.2 83.0 76.4 87.9
2(b) 2.1.2. Sezary syndrome 65 44.1 26.8 60.2 - - - 57.1 30.1 77.0 33.3 12.4 56.0
2(b) 2.2. Peripheral T-cell lymphoma 5,466 56.0 54.4 57.6 81.6 76.2 85.9 62.4 60.4 64.4 43.2 40.3 46.1
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 1,836 37.0 34.3 39.7 60.4 44.1 73.4 42.5 38.8 46.1 29.1 25.0 33.4
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 700 43.4 38.7 47.9 - - - 52.6 46.1 58.7 35.2 28.8 41.7
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 76 61.6 44.0 75.2 - - - 64.0 41.2 79.9 - - -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 1,189 58.1 54.9 61.2 85.2 78.7 89.9 62.0 58.1 65.7 32.0 25.5 38.8
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 43 26.8 13.9 41.5 - - - 26.8 12.0 44.2 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 65 13.3 5.4 25.0 - - - 16.5 5.3 33.1 11.9 3.0 27.5
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 1,055 81.1 77.2 84.4 - - - 85.8 81.7 89.1 73.0 65.0 79.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 502 90.9 86.3 94.0 - - - 94.5 89.1 97.2 81.3 69.2 89.0
2(b) 2.3. Adult T-cell leukemia/lymphoma 866 57.0 53.2 60.7 82.7 78.3 86.3 36.7 30.5 42.8 19.8 11.4 29.8
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 412 41.6 35.9 47.2 - - - 39.8 33.3 46.2 43.5 31.1 55.2
2(b) 2.5. T-cell large granular lymphocytic leukemia 140 64.4 52.3 74.2 - - - 75.8 59.1 86.4 54.7 37.7 68.9
2(b) 2.6. Prolymphocytic leukemia, T-cell 148 21.5 13.4 30.9 - - - 29.8 18.7 41.7 14.8 5.8 27.8
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 85 36.5 25.1 48.1 - - - 52.5 35.9 66.7 12.2 2.7 29.4
2(c) Non-Hodgkin lymphoma, unknown lineage 2,439 59.0 56.6 61.3 85.5 82.4 88.0 56.1 52.2 59.8 42.0 37.7 46.1
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 1,075 64.7 61.6 67.6 85.8 82.7 88.4 37.7 31.3 44.1 19.3 12.4 27.4
2(c) 2. Prolymphocytic leukemia, unknown lineage 57 48.5 33.5 62.0 - - - - - - 38.8 20.6 56.7
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 1,307 54.2 50.7 57.6 - - - 64.9 60.0 69.3 46.4 41.5 51.2
2(*) 1. Total precursor lymphoma/leukemiad 9,135 66.8 65.7 67.9 87.5 86.4 88.4 37.1 35.0 39.2 14.6 11.6 18.0
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 83 60.1 45.8 71.7 - - - 63.5 46.1 76.6 53.4 29.0 72.7
4 Lymphoid neoplasm, NOSc 4,491 48.8 46.9 50.7 84.5 72.3 91.6 61.4 58.6 64.0 39.8 37.2 42.4

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.